February 2001
Worldwide Biotech;Feb2001, Vol. 13 Issue 2, p6
Trade Publication
Reports that the company InterMune has filed a New Drug Submission with the Therapeutic Products Programme of Health Canada to market ACTIMMUNE in Canada for pediatric chronic granulomatous disease.


Related Articles

  • WHAT IT TAKES TO DEVELOP BETTER DRUGS FOR KIDS. Steven Leeder, J. // Scientist;Mar2012, Vol. 26 Issue 3, p36 

    The article focuses on the challenge facing the pediatric drug development. It states that determination of the relative contributions of genetic variation, environmental factors, developmental changes in drug-processing organs from birth to adulthood is the major challenge confronted in the...

  • Experimental designs for small randomised clinical trials: an algorithm for choice. Cornu, Catherine; Kassai, Behrouz; Fisch, Roland; Chiron, Catherine; Alberti, Corinne; Guerrini, Renzo; Rosati, Anna; Pons, Gerard; Tiddens, Harm; Chabaud, Sylvie; Caudri, Daan; Ballot, ClĂ©ment; Kurbatova, Polina; Castellan, Anne-Charlotte; Bajard, Agathe; Nony, Patrice // Orphanet Journal of Rare Diseases;2013, Vol. 8 Issue 1, Special section p1 

    Background: Small clinical trials are necessary when there are difficulties in recruiting enough patients for conventional frequentist statistical analyses to provide an appropriate answer. These trials are often necessary for the study of rare diseases as well as specific study populations e.g....

  • A Case of Excessive Masturbation Treated with Aripiprazole. Kul, Muslum; Baykan, Hayriye; Kandemir, Hasan // Klinik Psikofarmakoloji Bulteni;Mar2014, Vol. 24 Issue 1, p93 

    Childhood masturbation is defined as self-stimulation of the genitalia by a prepubertal child, frequently accompanied by symptoms like sweating, flushing and tachypnoea. Generally, no drug therapy is required in childhood masturbation. If the frequency of masturbation is too high and it is...

  • on the tip of your tongue...  // Laboratory News;Aug2013, p22 

    The article reports on the development of new sublingual spray developed by Norwich Research Park company LondonPharma for the treatment of children with severe malaria in Africa. It claims that the spray contains artemether, an extremely effective antimalarial agent, and can be applied by...

  • Congress vouches for priority review of childhood disease. Palmer, Roxanne // Nature Medicine;Feb2012, Vol. 18 Issue 2, p181 

    The article focuses on the introduced legislation of the U.S. Congress, the priority review vouchers (PRV), which aims in improving development of treatments for rare pediatric diseases. The PRV voucher program was originally offered by the Food and Drug Administration. Several critics,...

  • Parenteral presence during procedures increases care satisfaction.  // American Family Physician;3/1/1994, Vol. 49 Issue 4, p904 

    Presents a summary of the study conducted by Robert Vinci et al. on the impact of parental presence to pediatric care satisfaction. Importance of teaching parents interventions to reduce child's pain during invasive medical procedures.

  • How pediatricians treat their own kids. van der Meer, Antonia // Redbook;Feb93, Vol. 180 Issue 4, p146 

    Features various home remedies being practiced by pediatricians for common illnesses. Colds; Diarrhea; Fever; Sore throat; Vomiting; Splinters; Allergies; Chicken pox; Bitter medicine; Earache; Swimmer's ear; Sunburn; Teething; Colic; Diaper rash. INSET: When to call the doctor...

  • Lopinavir/ritonavir-based second line antiretroviral treatment in children at National Pediatric Hospital, Phnom Penh, Cambodia. Sam, Sophan; Ung, Vibol; Huot, Chantheany; Chan, Bunnthy; Yuvatha, Kdan; Courpotin, Christian; Adam, Guillaume; Ngin, Sopheak; Nerrienet, Eric; Chhour, Y. Meng // Retrovirology;2009 Supplement 1, Vol. 6, p1 

    An abstract of the article "Lopinavir/ritonavir-based second line antiretroviral treatment in children at National Pediatric Hospital, Phnom Penh, Cambodia," by Sophan Sam and colleagues, is presented.

  • Are the Kids Alright? Grant, Bob // Scientist;Mar2012, Vol. 26 Issue 3, p39 

    The article focuses on the Pediatric Research Equity Act (PREA) of 2003 and the Best Pharmaceuticals for Children Act (BPCA) of 2002, which are due to expire on October 1, 2012. It states that PREA requires companies that develop new drugs to perform clinical trials in children before it could...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics